. SR results by MAH Table 2 . REDEL results by ATC 2 nd level Table 3 . SR results by countries Access to original medicines is crucial to patients and supports the business goals of the pharmaceutical companies. Delay in the reimbursement process limits both of them, time to reimbursement of innovative medicines is significantly longer than recommended by the Transparency Directive. This study reviews the differences of reimbursement delays of the original outpatient care products in CEE countries (Austria, Bulgaria, the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and Slovenia). The subjects of the study are the original drugs authorized by the European Medicines Agency (EMA) or any national authorities of the above mentioned countries between 1st January 2007 and 1st July 2013. These originals were checked if they are part of the reimbursement system in the researched countries and the start of reimbursement is between 1st January 2010 and 1st July 2013. The reimbursement delays are counted from the time difference of the marketing authorization date and the beginning date of the reimbursement in each country.
The bases of comparison were 216 products and their ATC codes selected from the database of the EMA which were granted a marketing authorization between 1st January 2007 and 1st July 2013. After a four-level cleaning process of the database the EMA list contained 149 original ATCs. Additionally, 44 other INNs were found at least in one national list of the studied countries while comparing the EMA list with the national lists. In the case of these products the research studied the dates, when countries adopted them into their reimbursement system. The adoption was the subject of the study between 1st January 2010 and 1st July The results show that even threefold difference exists among the studied countries with regards to the reimbursement delay. An average of almost two years elapse until a producer can have the given product adopted into the reimbursement system in a country (the REDEL steadily increasing in the studied period, while the number of reimbursed products is decreasing). Total REDEL ranging between 403 (SLO) to 1295 (POL) days, while the overall SR varies from 7% (Romania) to 73% (Slovenia). Correlation between REDEL and public expenditure on pharmaceuticals is found, unlike other macroeconomic indicators. According to the results company efficiency very much depends on product portfolio. Further extensions in the scope of the study are possible, like study period or geographic extension, broadening the study with application delay analysis or to analyze different subsets of products (real innovation, incremental innovation, me-too). 
